In August 2025, Sanofi acquired the rights to develop and commercialize Redemplo in Greater China from Visirna Therapeutics, a majority-owned subsidiary of Arrowhead Pharmaceuticals.
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndromeUnderscores Sanofi's long-term commitment to ...
The Canadian actor revealed he tries to hit the gym about five times a week and is focused on growing more muscle ahead of ...
A research team at Tohoku University, in collaboration with Denka Company Limited and U-A Corporation, has developed a ...
11hon MSN
‘Heated Rivalry’ Star Hudson Williams Took Us Through His Sweaty, Glute-Building Workout Routine
Heated Rivalry star Hudson Williams shares the total-body workout he uses to build up his butt. Watch his work out and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback